MPL Mutation Analysis by NGS
Use
Exon 10 MPL mutations, most commonly W515 and S505, are present in approximately 5‑10% of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET). MPL and CALR mutations have been associated with increased risk of myelofibrotic transformation in ET cases. (References: PMID: 36347013)
Special Instructions
This test may be ordered separately (if JAK2 analysis, specifically JAK2 V617F, is already performed), as a reflex from JAK2 V617F Mutation Analysis, or as part of the MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12‑15, CALR, and MPL. Note: This assay replaces the former MPL Mutation Analysis performed by bi‑directional sequencing. NY samples are still processed by bi‑directional sequencing until further notice.
Limitations
Not provided.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
1‑2 mL in EDTA tube
Minimum Volume
Not provided
Container
EDTA tube (Sodium Heparin acceptable)
Storage Instructions
Refrigerate before shipping, ship same day; use cold pack not in direct contact; do not freeze